Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation
- 1 August 2009
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 36 (6) , 591-603
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesisPharmacology & Therapeutics, 2004
- Peptide Receptors as Molecular Targets for Cancer Diagnosis and TherapyEndocrine Reviews, 2003
- Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cellsNuclear Medicine and Biology, 2003
- [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Current and Potential Therapeutic Uses of Lanthanide RadioisotopesCancer Biotherapy and Radiopharmaceuticals, 2000
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic useEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypesBiochemical Pharmacology, 1995
- Growth factor and peptide receptors in small cell lung cancerLife Sciences, 1993
- Therapeutic use and Perspectives of Synthetic Peptides in OncologyActa Oncologica, 1993
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancerNature, 1985